Key findings at the highest dose (12mg weekly): Up to 24% mean body weight reduction over 48 weeks Significant reductions in fasting glucose and insulin resistance markers Meaningful reductions in liver fat content, relevant for participants with metabolic-associated fatty liver disease Once-weekly subcutaneous dosing was generally well-tolerated For context, semaglutide at its approved dose achieves approximately 1517% body weight reduction over 68 weeks
User 41 reported severe anxiety, bloating, headaches, and gut pain after oral BPC-157 use
This is the minimum standard for serious research use, and anything below this threshold introduces too many variables to produce reliable data
The practice involves paying attention to hunger and fullness cues, eating slowly without distractions, and understanding how food impacts your mood and health
This can make it easier to make healthier food choices
The 4mg escalation dose is a clean 80 units